Nonmyeloablative HSCT has the theoretical advantage, based on
the experience with malignancies, of obtaining allogeneic engraftment
with a very low, early mortality rate. However, increased
reliance on immunologic effects that is required to sustain engraftment
requires a prudent approach to the wide use of this regimen,